Drug Profile
Nitroxylated albumin - SynZyme Technologies
Alternative Names: VACNOLatest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator SynZyme Technologies
- Class Albumins; Nitrogen oxides
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Stroke in USA (Parenteral)
- 02 Aug 2016 Nitroxylated albumin - SynZyme is available for licensing - http://www.synzyme.com/gallery.html
- 02 Aug 2016 Preclinical trials in Stroke in USA (Parenteral)